Methylation-induced loss of miR-484 in microsatellite-unstable colorectal cancer promotes both viability and IL-8 production via CD137L

The Journal of Pathology
Qian MeiWeidong Han

Abstract

Colorectal cancer (CRC) exhibiting MSI (microsatellite instability) represents a well-defined subtype characterized by a deficient mismatch repair pathway and typical clinico-pathological features. Our objective was to identify the entire miRNome and its molecular pathological roles in MSI CRCs. We profiled miRNA expression in MSI CRCs and compared it with MSS counterparts. Microarray and qRT-PCR analysis identified eight miRNAs that could distinguish the MSI status of CRCs. MiR-484 was the most significantly decreased miRNA in MSI CRCs, primarily mediated by the CpG island methylator phenotype. MiR-484 functions as a tumour suppressor to inhibit MSI CRC cell viability in vitro and in vivo. Moreover, miR-484 repressed CD137L expression and thereby attenuated IL-8 production by MSI CRC cells. Our results contribute to a better understanding of the roles of dysregulated miRNAs in the distinct phenotypic features of MSI CRCs and indicate an option for early diagnosis and gene therapy for these patients.

References

Aug 18, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·H R SalihP A Kiener
Jan 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S PopatR S Houlston
Nov 30, 2005·Nucleic Acids Research·Caifu ChenKarl J Guegler
Mar 24, 2006·The British Journal of Surgery·K SöreideJ P A Baak
Feb 28, 2008·Proceedings of the National Academy of Sciences of the United States of America·Louis C DoreMitchell J Weiss
Sep 19, 2009·Nature Reviews. Genetics·Carlo M Croce
Feb 24, 2010·Nature Reviews. Clinical Oncology·Madeleine HewishAlan Ashworth
Mar 4, 2010·International Journal of Cancer. Journal International Du Cancer·Matthias KloorMagnus von Knebel Doeberitz
Aug 17, 2010·FEBS Letters·Sonia A Melo, Manel Esteller
Feb 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Frank A Sinicrope, Daniel J Sargent
Jun 1, 2012·The Cancer Journal·Aaron J SchetterCurtis C Harris
May 24, 2013·Proceedings of the National Academy of Sciences of the United States of America·Andrea VecchioneCarlo M Croce
Jun 5, 2014·BioMed Research International·Fengfeng WangBenjamin Y M Yung
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Oct 25, 2014·Cancer Management and Research·Yujuan DongSimon Sm Ng

❮ Previous
Next ❯

Citations

Feb 5, 2016·Biochemical and Biophysical Research Communications·Chengcao SunDejia Li
Dec 10, 2015·Genes, Chromosomes & Cancer·Musaffe TunaGeorge A Calin
May 21, 2016·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Martha L SlatteryRoger K Wolff
Oct 30, 2016·Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals·Mozhdeh ZamaniPooneh Mokarram
Jun 25, 2016·World Journal of Gastroenterology : WJG·Xiang LiWei-Dong Han
Aug 18, 2017·Wiley Interdisciplinary Reviews. RNA·Ovidiu BalacescuCatalin Marian
Jul 27, 2018·Canadian Journal of Gastroenterology & Hepatology·Yixin YangWei Wang
Feb 23, 2020·Cancer Biomarkers : Section a of Disease Markers·Andrea RitterThalia Erbes
Feb 18, 2020·Cancer Biomarkers : Section a of Disease Markers·Weijia ZhangHai Zeng
Dec 14, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nan LiGuopei Zheng
Jun 26, 2021·OncoTargets and Therapy·Fangyuan CaoXinshan Jia

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.